Antisense therapeutics: Nuclear RNA more susceptible to knockdown

Nature Reviews Drug Discovery

Volumn 11, Issue 9, 2012, Pages 674-

  Tse, Man Tsuey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRASCRIPT 1; MYOTONIC DYSTROPHY PROTEIN KINASE; NUCLEAR RNA; RIBONUCLEASE; TRANSCRIPTOME; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; DISEASE MODEL; DOSE RESPONSE; DRUG MECHANISM; DRUG SPECIFICITY; DRUG UPTAKE; GENE SILENCING; HINDLIMB; MUSCLE FUNCTION; MYOTONIC DYSTROPHY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA DEGRADATION; TRANSGENIC MOUSE; TREATMENT DURATION; TRINUCLEOTIDE REPEAT; WILD TYPE;

EID: 84866107199     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3825     Document Type: Note

References (2)

1. ORIGINAL RESEARCH PAPER Wheeler, T. M. et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115 (2012)
2. FURTHER READING Muntoni, F. & Wood, M. J. A. Targeting RNA to treat neuromuscular disease. Nature Rev. Drug Discov. 10, 621-637 (2011)